FDA OKs Gender-Neutral Language for Isotretinoin iPLEDGE Risk Management Program
Joshua Safer, MD, comments on the gender-neutral language for the new FDA approved Isotretinoin iPLEDGE Risk Management Program.
Joshua Safer, MD, comments on the gender-neutral language for the new FDA approved Isotretinoin iPLEDGE Risk Management Program.
